ADAM 10 – A Biomarker for Traumatic Brain Injury

Reliable blood based biomarkers are urgently needed for early diagnosis of TBI, particularly mild TBI (mTBI) cases such as sport concussions which are often ignored by victims and clinicians (due to lack of diagnostic imaging evidence) and may lead to catastrophic consequences in repeated concussions. Using immunoblotting with a commercial antibody, we have shown significant increase in plasma levels of ADAM 10 (a distintegrin and metalloproteinase-10) protein in blast exposed rats and concussive athletes. We therefore propose plasma ADAM 10 as a potential diagnostic biomarker for mTBI. Clinical validation of this TBI biomarker is ongoing through a collaboration with the Centre for Drug Research and Development in Vancouver, Canada